

## press release

### **Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model**

- *Hims & Hers customers will soon have access to FDA-approved injectables Ozempic® and Wegovy®, and Wegovy® pill, the first and only oral GLP-1 approved for weight loss, at Novo Nordisk's self-pay prices*
- *The Company welcomes the decision of Hims & Hers to shift its GLP-1 business model towards FDA-approved medicines*
- *Novo Nordisk's focus remains on delivering innovation, powered by our distinct semaglutide molecule, to US consumers, meeting people wherever they choose to get their care*

**Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026** – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims & Hers will offer access to FDA-approved Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg and Wegovy® (semaglutide) tablets 1.5 mg, 4 mg, 9 mg, and 25 mg and injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, to US consumers at the same affordable self-pay prices as other telehealth platforms. We welcome Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines. Hims & Hers will no longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved alternatives when clinically appropriate in consultation with a healthcare professional.

“This agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,” said Mike Doustdar, President and CEO of Novo Nordisk. “Wegovy® is not simply an obesity therapy. It is a clinically proven treatment that helps adults with obesity lose weight while also reducing the risk of cardiovascular events in patients who also have heart disease. That combination of powerful weight loss efficacy and proven risk reduction is what makes Wegovy® truly distinct. We all want better health. Our goal is simple: ensure that every patient who can benefit from our medicines has the opportunity to access them, wherever they choose to receive care.”

Patients using Hims & Hers will soon have access to the full range of FDA-approved semaglutide medicines, including the Wegovy® pill which delivers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials. All doses of Ozempic® (injectable) and Wegovy® (injectable and pill) are broadly available nationwide for Americans across 70,000+ pharmacies, our own direct to consumer platform NovoCare® Pharmacy, and select telehealth providers and digital platforms.

In OASIS 4, Wegovy® pill demonstrated an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.\*<sup>1</sup> When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy® pill compared to about 2% (2.4%) for placebo.\*\*<sup>1</sup> Common adverse reactions were similar to those previously seen in clinical trials with Wegovy® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.<sup>1</sup>

Along with diet and exercise, Wegovy® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.

Ozempic® is approved for adults with type 2 diabetes along with diet and exercise to improve blood sugar control and to reduce the risk of MACE such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

In light of this agreement, Novo Nordisk is dismissing our patent infringement lawsuit against Hims & Hers while reserving the right to refile in the future.

\* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.

\*\* Based on the treatment policy estimand: treatment effect regardless of if patients stayed on treatment or took other weight loss therapies.

#### **About OASIS 4**

OASIS 4 was a 64-week phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI  $\geq$  30 kg/m<sup>2</sup>) or overweight (BMI  $\geq$  27 kg/m<sup>2</sup>) with one or more weight-related comorbidities.<sup>1</sup> People with diabetes were excluded.<sup>1</sup> OASIS 4 included a 64-week treatment period, including a 12-week dose escalation, and a 7-week off-treatment follow-up period.

In total, 307 participants were randomized in a 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, alongside lifestyle intervention for 64 weeks.<sup>1</sup>

For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb). versus 31% taking placebo (from a baseline body weight of 231 lb.).<sup>1</sup>

### **What is Wegovy®?**

Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:

- reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off.

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy® injection is safe and effective:

- to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
- to help children under 12 years of age lose weight and keep the weight off

It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.

### **Important Safety Information**

#### **What is the most important information I should know about Wegovy®?**

**Wegovy® may cause serious side effects, including:**

- **Possible thyroid tumors, including cancer.** Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

**Do not use Wegovy® if:**

- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® injection or Wegovy® tablets. See symptoms of serious allergic reaction in "**What are the possible side effects of Wegovy®?**"

**Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:**

- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy® tablets. It is not known if Wegovy® when received through an injection passes into your breast milk

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

**What are the possible side effects of Wegovy®?**

**Wegovy® may cause serious side effects, including:**

- **inflammation of your pancreas (pancreatitis).** Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back
- **gallbladder problems.** Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
- **increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas.** This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger,

confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery

- **dehydration leads to kidney problems.** Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
- **serious allergic reactions.** Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **change in vision in people with type 2 diabetes.** Tell your healthcare provider if you have changes in vision during treatment with Wegovy®
- **increased heart rate.** Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures

**The most common side effects of Wegovy® may include:** nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.

Please click [here](#) for Prescribing Information including Boxed Warning and Medication Guide for Wegovy®.

### What is Ozempic®?

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:

- along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes
- to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease
- to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease

It is not known if Ozempic® is safe and effective for use in children.

## Important Safety Information

**Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.**

**What is the most important information I should know about Ozempic®?**

**Ozempic® may cause serious side effects, including:**

- **Possible thyroid tumors, including cancer.** Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic® and medicines that work like Ozempic® caused thyroid tumors, including thyroid cancer. It is not known if Ozempic® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Ozempic® if you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

**Do not use Ozempic® if:**

- you or any of your family have ever had MTC or if you have MEN 2
- you are allergic to semaglutide or any of the ingredients in Ozempic®. See symptoms of serious allergic reaction in "**What are the possible side effects of Ozempic®?**"

**Before using Ozempic®, tell your health care provider if you have any other medical conditions, including if you:**

- have or have had problems with your pancreas
- have a history of diabetic retinopathy
- have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Ozempic® will harm your unborn baby or pass into your breast milk. You should stop using Ozempic® at least 2 months before you plan to become pregnant

**Tell your health care provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.

**What are the possible side effects of Ozempic®?**

**Ozempic® may cause serious side effects, including:**

- **inflammation of your pancreas (pancreatitis).** Stop using Ozempic® and call your health care provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- **changes in vision.** Tell your health care provider if you have changes in vision during treatment with Ozempic®

- **low blood sugar (hypoglycemia).** Your risk for getting low blood sugar may be higher if you use Ozempic® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. **Signs and symptoms of low blood sugar may include:** dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling jittery
- **dehydration leading to kidney problems.** Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your health care provider right away if you have nausea, vomiting, or diarrhea that does not go away
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use Ozempic®. Tell your health care provider if you have stomach problems that are severe or will not go away
- **serious allergic reactions.** Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **gallbladder problems.** Gallbladder problems have happened in some people who take Ozempic®. Tell your health care provider right away if you get symptoms which may include: pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** Ozempic® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your health care providers that you are taking Ozempic® before you are scheduled to have surgery or other procedures

**The most common side effects of Ozempic® may include** nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.

Please click [here](#) for Prescribing Information and Medication Guide for Ozempic®.

### **About Novo Nordisk**

*Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit [novonordisk-us.com](http://novonordisk-us.com), Facebook, Instagram, and X.*

## Contacts for further information

### Media:

#### Liz Skrbkova (US)

+1 609 917 0632

[USMediaRelations@novonordisk.com](mailto:USMediaRelations@novonordisk.com)

#### Ambre James-Brown (Global)

+45 3079 9289

[Globalmedia@novonordisk.com](mailto:Globalmedia@novonordisk.com)

### Investors:

#### Frederik Taylor Pitter (US)

+1 609 613 0568

[fpitr@novonordisk.com](mailto:fpitr@novonordisk.com)

#### Jacob Martin Wiborg Rode (Global)

+45 3075 5956

[jrde@novonordisk.com](mailto:jrde@novonordisk.com)

#### Sina Meyer (Global)

+45 3079 6656

[azey@novonordisk.com](mailto:azey@novonordisk.com)

#### Christoffer Sho Togo Tullin (Global)

+45 3079 1471

[cftu@novonordisk.com](mailto:cftu@novonordisk.com)

#### Max Ung (Global)

+45 3077 6414

[mxun@novonordisk.com](mailto:mxun@novonordisk.com)

#### Alex Bruce (Global)

+45 34 44 26 13

[axeu@novonordisk.com](mailto:axeu@novonordisk.com)

### References:

1. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. *N Engl J Med*. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.